http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20071023-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 |
| filingDate | 2007-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b2b0bea90373d33540cbc22d39db384 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c1c8e9632ae99b4b36458597295a56c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14a90ae821bcbf2004901b7dcdb6f746 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a436b9bac24486364ac8bfe1505cd1d8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee9adbd5b1287f4279a79f4a08a3c08a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59a12885ea105b0ad171910f0b6fda5b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79faaa36863f46d3354f6064184246f0 |
| publicationDate | 2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20071023-A1 |
| titleOfInvention | AZACYCLYLAMINES-N-SUBSTITUTED AS ANTAGONISTS OF HISTAMINE-3 |
| abstract | REFERS TO COMPOUNDS DERIVED FROM AZACICLYLAMINE N-SUBSTITUTED FROM FORMULA (I) WHERE X IS CO, CH2 OR SOm, WHERE m IS FROM 0 TO 2; n AND p ARE EACH FROM 1 TO 3; R1 AND R2 ARE EACH H, ALKYL (C1-C10) OR R1 AND R2 ARE TAKEN TOGETHER WITH THE ATOM TO WHICH THEY ARE UNITED TO FORM A RING OF 4 TO 7 MEMBERS THAT HAS 1 TO 2 HETEROATOMES SELECTED FROM N, OUS, OPTIONALLY SUBSTITUTED WITH HALOGEN, NITRO, CN, OXO, OH, AMONG OTHERS; R3 IS NR4R5, ARYL (C6-C20) OR HETEROARYL OF 5 TO 11 MEMBERS OPTIONALLY REPLACED WITH HALOGEN, NITRO, CN, OXO, OH, AMONG OTHERS, WHERE R4 AND R5 ARE TAKEN TOGETHER WITH THE ATOM TO WHICH THEY ARE UNITED BICYCLE, TRICYCLE OR TETRACYCLIC RING OF 9 TO 15 MEMBERS CONTAINING 1 TO 3 HETEROATOMS SELECTED FROM N, OUS; R6 AND R7 ARE EACH H, HALOGEN, ALKYL (C1-C10), CYCLOALKYL (C3-C10), AMONG OTHERS, OPTIONALLY SUBSTITUTED WITH HALOGEN, NITRO, CN, OXO, OH, AMONG OTHERS; R8 AND R9 ARE EACH H, ALKYL (C1-C10), CYCLOALKYL (C3-C10) OR ARYL (C6-C20) OPTIONALLY SUBSTITUTED WITH HALOGEN, NITRO, CN, OXO, OH, AMONG OTHERS. PREFERRED COMPOUNDS ARE: N, N-DIMETHYL-1- {4 - [(2-PHENYL-1H-BENZYMIDAZOL-1-IL) METHYL] -BENZOIL} PYRROLIDIN-3-ILAMINE, N, N-DIMETHYL-1- {4 - [(6-FLUORO-1H-BENZIMIDAZOL-1-IL) METHYL] -BENZOYL} PYRROLIDIN-3-ILAMINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE INHIBITORS OF THE HISTAMINE H3 RECEPTOR, BEING USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE |
| priorityDate | 2006-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3609161 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559484 |
Total number of triples: 31.